Recent Advances in Curcumin-Based Nanoformulations in Diabetes Publisher Pubmed



Ataei M^{1, 2} ; Gumpricht E³ ; Kesharwani P^{4, 5} ; Jamialahmadi T⁶ ; Sahebkar A^{6, 7} Show Affiliations
Source: Journal of Drug Targeting Published:2023

Abstract

Diabetes is predicted to affect 700 million people by the year 2045. Despite the potential benefits for diabetics, curcumin’s low bioavailability significantly reduces its utility. However, newer formulation methods of decreasing particle size, such as through nanotechnological advances, may improve curcumin’s bioavailability and cell-absorption properties. Various curcumin nanoformulations such as nanofibers, nanoparticles-like nanostructured lipid carriers (NLCs), Solid Self-Nanoemulsifying Drug Delivery Systems (S-SNEDDS) and nanohydrogels have been evaluated. These studies reported increased bioavailability of nanoformulated curcumin compared to free curcumin. Here, we provide a detailed review of the antidiabetic effects of nanocurcumin compounds and subsequent effects on diabetic complications. Overall, various nanocurcumin formulations highly increase curcumin water-solubility and bioavailability and these safe formulations can positively affect managing some diabetes-related manifestations and complications. Moreover, nanocurcumin efficacy in various diabetes complications is discussed. These complications included inflammation, neuropathy, depression, anxiety, keratopathy, cataract, cardiomyopathy, myocardial infarction (MI), nephropathy, erectile dysfunction and diabetic wound. Moreover, several nanocurcumin formulations improved wound healing in the diabetic. However, few studies have been performed in humans, and most results have been reported from cellular and animal studies. Therefore, more human studies are needed to prove the antidiabetic effects of nanocurcumin. © 2023 Informa UK Limited, trading as Taylor & Francis Group.